GlassScriptPhysician profile
Jeffrey C Robinson
NPI 1053587816
$51,168.37
in general payments reported to CMS, 2019-2025
9 companies · $20K in 2025
The $20K reported for 2025 was more than what 95% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,990 · 2020: $3,743 · 2021: $4,268 · 2022: $7,350 · 2023: $944 · 2024: $5,885 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Travel and Lodging: $3,077 · Food and Beverage: $2,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,150.00 |
| Travel and Lodging | $3,076.69 |
| Food and Beverage | $2,590.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $28,356.56 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $12,120.62 | 2022-2025 | Winrevair |
| United Therapeutics Corporation | $8,595.87 | 2019-2025 | Remodulin, Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $1,830.00 | 2021 | |
| Boston Scientific Corporation | $141.78 | 2025 | General - Vascular Intervention, Jetstream Sc |
| Johnson & Johnson Health Care Systems INC. | $107.30 | 2024 | Opsumit, Uptravi |
| Insmed, INC. | $16.24 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.